山东三元生物科技股份有限公司 简式权益变动报告书 上市公司名称：山东三元生物科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：三元生物 股票代码：301206 信息披露义务人：山东省鲁信资本市场发展股权投资基金合伙企业（有限合 伙） 住所：山东省淄博市高新区鲁泰大道 51 号高分子创新园 A 座 2312 房间 通讯地址：山东省济南市历下区奥体西路 2788 号鲁信集团 26 层 股份变动性质：股份减少（持股比例减少至 5%以下） 签署日期：2025 年 5 月 13 日 1 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容与 格式准则第 15 号——权益变动报告书》及相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在山东三元生物科技股份有限公司中拥有权 益的股份变动情况。 截至本报告 ...

Group 1 - The sugar substitute concept declined by 0.82%, ranking among the top declines in the concept sector, with companies like Baolingbao, Bailong Chuangyuan, and Chenguang Biotech experiencing significant drops [1][2] - Among the sugar substitute stocks, 8 saw price increases, with Zhonghua International, Luxin Investment, and Xinghu Technology rising by 1.37%, 1.34%, and 1.09% respectively [1][2] - The sugar substitute sector experienced a net outflow of 118 million yuan, with 17 stocks seeing net outflows, and 5 stocks with outflows exceeding 10 million yuan, led by Jinhai Biological with a net outflow of 44.98 million yuan [2][3] Group 2 - The top net inflow stocks in the sugar substitute sector included Jinhai Industrial, Rhine Biological, and Shengquan Group, with net inflows of 16.36 million yuan, 12.29 million yuan, and 5.05 million yuan respectively [2][3] - The outflow leaderboard for the sugar substitute sector featured Jinhai Biological, Yasheng Group, and Baolingbao, with respective outflows of 44.98 million yuan, 25.20 million yuan, and 22.92 million yuan [2][3] - The trading activity in the sugar substitute sector showed varied turnover rates, with Baolingbao at 14.36% and Jinhai Biological at 6.48% [2][3]

为进一步加强与投资者的互动交流，山东三元生物科技股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP, 参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。届时公 司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与！ 特此公告 山东三元生物科技股份有限公司 证券代码：301206 证券简称：三元生物 公告编号：2025-048 山东三元生物科技股份有限公司 关于参加 2025 年山东辖区上市公司投资者网上集体接 待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2025 年 5 月 13 ...

Summary of Conference Call on D-Allulose Industry Overview - The focus is on the D-Allulose market, a new segment within the sugar substitute industry, which is gaining traction due to recent policy support and health trends [1][2]. Key Points and Arguments 1. **Policy Support**: The Ministry of Commerce and the National Health Commission, along with 12 other departments, issued a notice promoting healthy consumption, emphasizing dietary guidance for patients with hypertension, type 2 diabetes, hyperlipidemia, and obesity. This highlights the importance of health-focused food products like D-Allulose [1]. 2. **Health Benefits**: D-Allulose is recognized for its potential to lower blood pressure and lipid levels, as well as its role in preventing type 2 diabetes, aligning with the government's health initiatives [1]. 3. **Regulatory Approval**: The National Health Commission completed a public consultation on D-Allulose on April 20, marking its path towards compliance and potential market entry [1]. 4. **Market Potential**: D-Allulose is expected to replace existing sugar substitutes in beverages and food, indicating a significant market opportunity. The global approval history of D-Allulose spans 14 years, with countries like the USA, Japan, Mexico, Canada, South Korea, and Australia recognizing it as a food ingredient [2]. 5. **GRAS Status**: D-Allulose is classified as GRAS (Generally Recognized As Safe) by FEMA, allowing its use in beverages and dairy products, further enhancing its marketability [2]. 6. **Health Advantages**: In addition to its sweetening properties, D-Allulose offers benefits such as promoting the Maillard reaction, lowering blood sugar and lipid levels, aiding liver detoxification, and preventing obesity and type 2 diabetes [2]. 7. **Company Developments**: - **Baolingbao**: Currently constructing a 30,000-ton D-Allulose project, which will be actively promoted for consumer sales once approved for domestic use [3]. - **Bailong Chuangyuan**: Has a crystallized sugar project with an annual capacity of 15,000 tons, which can produce 5,000 tons of D-Allulose [3]. Additional Important Information - D-Allulose is positioned as a new star among sweeteners, with no reported side effects and the ability to release GLP-1, which can combat obesity and diabetes [2]. - Companies to watch in this sector include Bailong Chuangyuan, Baolingbao, Sanyuan Biological, and Huakang Co. [2].

Summary of Conference Call Records Industry Overview - The records focus on the **sugar substitute industry**, specifically the emerging segment of **D-Allulose** as a health-oriented sweetener. The industry is experiencing significant regulatory changes and market opportunities due to new health consumption policies in China [1][2]. Key Points and Arguments - The **Ministry of Commerce and the National Health Commission** of China, along with 12 other departments, issued a notice on promoting health consumption, emphasizing the need to improve healthy dietary consumption levels. This includes guidance for healthcare institutions to provide dietary and exercise advice for patients with hypertension, type 2 diabetes, hyperlipidemia, and obesity [1][2]. - The notice highlights the importance of **food health products**, indicating a high level of attention towards health-oriented sweeteners like **D-Allulose**, which has benefits in lowering blood pressure, reducing lipids, and preventing type 2 diabetes [1][2]. - D-Allulose is on the verge of regulatory approval in China, marking a significant milestone for the domestic sugar substitute market. The product has a long history of approval in other countries, including the United States, Japan, Mexico, Canada, South Korea, and Australia/New Zealand [3]. - D-Allulose is recognized as a **GRAS (Generally Recognized As Safe)** product by FEMA, allowing its use in beverages and dairy products. Canada has also approved it as a natural health product ingredient [3]. - The product not only shares the advantages of **Erythritol** but also promotes the Maillard reaction, lowers blood sugar and lipids, aids liver detoxification, and helps prevent obesity and type 2 diabetes [3]. Company Insights - **Baolingbao** is currently constructing a **30,000-ton D-Allulose project**, which is in the building phase. The company plans to actively promote sales to consumers once D-Allulose is approved for use in China [4]. - **Bailong Chuangyuan** has a **15,000-ton crystalline sugar project** that can produce **5,000 tons of D-Allulose** [4]. Additional Important Content - The records suggest that D-Allulose is emerging as a new star among sweeteners, with no reported side effects. It has similar effects to GLP-1 (glucagon-like peptide-1), which can help combat obesity and diabetes [3]. - The market potential for D-Allulose is vast, as it is expected to replace existing sugar substitutes in beverages and food products, indicating a significant growth trend in the industry [3]. Conclusion - The regulatory environment is becoming increasingly favorable for D-Allulose, positioning it as a key player in the health-oriented sweetener market. Companies like Baolingbao and Bailong Chuangyuan are poised to capitalize on this trend, potentially leading to substantial market growth and investment opportunities in the sector [3][4].

截至5月9日收盘，代糖概念上涨0.64%，位居概念板块涨幅第3，板块内，9股上涨，百龙创园、金禾实 业、保龄宝等涨幅居前，分别上涨8.33%、3.52%、3.26%。跌幅居前的有金河生物、华资实业、星湖科 技等，分别下跌2.52%、1.61%、1.61%。 | 600783 | 鲁信创 投 | -0.08 | 0.44 | 290.14 | 7.42 | | --- | --- | --- | --- | --- | --- | | | 中化国 | | | | | | 600500 | | -0.54 | 0.35 | 275.51 | 6.01 | | | 际 | | | | | | 605300 | 佳禾食 | -0.36 | 0.92 | 234.25 | 4.57 | | | 品 | | | | | | 000930 | 中粮科 | -0.36 | 0.55 | 109.41 | 1.91 | | | 技 | | | | | | 603968 | 醋化股 | -0.37 | 0.96 | 3.77 | 0.18 | | | 份 | | | | | | | 蔚蓝生 | | | | | | 603739 ...

A股代糖概念板块震荡上升，百龙创园封板涨停，亚盛集团涨超4%，金禾实业涨近4%，红棉股份、三 元生物等跟涨。 ...

Core Insights - The company aims to enhance its market competitiveness in the food, nutrition, and beauty sectors by investing in Peisheng Biotechnology to promote the application of new raw materials in consumer products [1][2] - The establishment of Beijing Kaiyuan Juliy aims to leverage the capital and talent resources in the capital city to improve the company's professional capabilities in business expansion and capital operations, driving a dual strategy of "industry + capital" [1] Product Pricing and Market Strategy - The sales prices of products such as erythritol, blended sugars, and allulose will fluctuate based on specifications, business conditions, and market competition, with a dynamic adjustment throughout the year [1] - The company has a competitive edge in production technology and cost control for tagatose, which is currently in an active promotion phase, with market pricing being continuously optimized based on market feedback [1] New Product Development - The company is committed to innovation-driven growth, focusing on synthetic biology and advancing new product research and industrialization [2] - A new 10,000-ton production line for allulose is under rapid construction, aiming to secure a first-mover advantage in the fast-growing market once approved for domestic use [2] - The existing 85,000-ton erythritol production line is undergoing upgrades to enable flexible manufacturing capabilities across multiple products, significantly reducing new product line construction costs and enhancing market responsiveness [2] - The company is optimizing production processes for high-activity biological raw materials like glycerol glycosides and sweet tea glycosides, with plans for small-scale production based on technology maturity and market demand [2]

Group 1: Company Strategy and Investments - The core purpose of investing in Peisheng Biotechnology is to promote the application of new raw materials in C-end products, enhancing market competitiveness in food, nutrition, and beauty sectors [4] - The establishment of Beijing Kaiyuan Juliy aims to leverage talent and resources in the capital to enhance business expansion and capital operation professionalism [4] Group 2: Production Capacity and Flexibility - The 85,000-ton project is an upgrade of the existing erythritol production line, enabling flexible manufacturing of multiple products based on market demand [4] - The 80,000-ton project focuses on upstream integration, producing liquid glucose from corn, ensuring stable raw material supply for various products [4] Group 3: Employee Stability - The number of employees remains stable, with no layoffs reported, emphasizing talent cultivation and a supportive work environment [4] Group 4: Market Performance and Sales - Erythritol revenue was 515.4 million yuan, with a sales price exceeding 10,000 yuan/ton, leading to a sales volume of less than 50,000 tons due to industry competition and EU anti-dumping measures [7] - Domestic market sales increased by 70.23% year-on-year, with the number of domestic distributors rising by 117, reflecting the growing demand for reduced sugar products [9] Group 5: Regulatory Challenges - The EU imposed a 156.7% anti-dumping duty on the company's products, effective for five years, prompting adjustments in production processes to comply with cost assessment rules [10] - The company is actively responding to the US "double anti" investigation, which has impacted sales in the US market, and is developing contingency plans [14] Group 6: Product Development and Innovation - The second 10,000-ton production line for allulose is under rapid construction, aiming to capture market share once approved for domestic use [13] - The company is enhancing production processes for high-activity biological raw materials, expanding its product range beyond erythritol [13] Group 7: Future Outlook and Shareholder Returns - The company has a three-year shareholder return plan (2024-2026) focusing on stable profit distribution while considering profitability and cash flow [7] - The company aims to diversify its market strategy, reducing reliance on single markets and enhancing resilience against policy risks [15]

Core Insights - Shandong Sanyuan Biotechnology Co., Ltd. reported a revenue of 712.90 million yuan for 2024, representing a year-on-year growth of 42.72% [1][2] - The net profit attributable to shareholders reached 104.95 million yuan, an increase of 87.47% compared to the previous year [1][2] - The company's net profit after deducting non-recurring gains and losses was 102.48 million yuan, also reflecting an 87.04% year-on-year growth [1][2] Financial Performance - In Q4 2024, the company achieved a revenue of 198 million yuan, which is a 33.49% increase year-on-year [2] - The net profit for Q4 2024 was 23.94 million yuan, up 67.34% from the same quarter last year [2] - The net profit after deducting non-recurring gains and losses for Q4 2024 was 23.01 million yuan, showing a 64.73% increase year-on-year [2] Profitability Metrics - The gross margin for 2024 was reported at 11.11%, an increase of 8.06 percentage points compared to the previous year [3] - The net profit margin for 2024 was 14.72%, which is an increase of 3.51 percentage points year-on-year [3] Expense Analysis - Sales expenses increased by 24.81% year-on-year, while management expenses rose by 27.16% [3] - Research and development expenses decreased by 18.61% compared to the previous year [3] Cash Flow Overview - The net cash flow from operating activities decreased by 123.82% year-on-year, primarily due to a change in payment methods and the need to repay previously issued bank acceptance bills [3] - The net cash flow from investing activities increased by 159.15% year-on-year, mainly due to the redemption of certain large bank deposits [3] - The net cash flow from financing activities grew by 31.19% year-on-year, attributed to higher dividend distributions in 2023 [3] Company Background - Sanyuan Biotechnology was established on March 4, 2022, and was listed on February 10, 2022 [3] - The company's main business includes the research, production, and sales of food additives, specifically erythritol and its compound products [3]